Business
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
Data support the Company’s pipeline of innovative product candidates aimed at improving the quality-of-life for patients battling kidney disease LOS ALTOS,
About this update from Unicycive Therapeutics, Inc.
[{"type":"text","content":"Data support the Company’s pipeline of innovative product candidates aimed at improving the quality-of-life for patients battling kidney disease\nLOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two abstracts to be presented as posters and one publication in the Abstract Supplement at the American Society of Nephrology’s (ASN) Kidney Week 2022 taking place November 3-6, 2022 in Orlando, Fla. UNI-494 is a novel proprietary drug targeting the SUR2 subunit of the mitochondrial KATP channel activator that reduces oxidative stress and restores mitochondrial function. UNI-494’s novel mechanism of action may also hold promise for indications in which mitochondrial dysfunction is implicated such as chronic kidney disease, liver disease (alcoholic hepatitis, hepatic encephalopathy) and ophthalmic disease (dry AMD, macular degeneration etc). Renazorb is an advanced phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). “Kidney Week 2022 offers an ideal opportunity to share the favorable results from two of Unicycive’s important product candidates with the nephrology community,” said Shalabh Gupta, M.D., Chief Executive Officer. “We continue to build on the body of clinical and scientific evidence to support the potentially best-in-class product profiles for Renazorb to treat hyperphosphatemia and for UNI-494 to reduce oxidative stress and restore mitochondrial function in a number of potential indications, including Acute Kidney Injury.” The following abstracts have been accepted for presentation at the NKF Spring Clinical Meeting: Poster Title:“Preclinical Pharmacokinetics of a Novel Nicorandil Prodrug”Session Title:Pharmacology (PO1900)Poster #3760757Date/Time:Friday, November 4, from 10:00 am – 12:00 pm Eastern TimePoster Board #:FR-PO220 Poster Title:“Lanthanum Dioxycarbonate Effectively Reduces Urinary Phosphate Excretion in Healthy Volunteers”Session Title:Vascular Calcification, Nephrolithiasis, Bone (PO0402)Poster #3760842Date/Time:Saturday, November 5, from 10:00 am – 12:00 pm Eastern TimePoster Board #:SA-PO171 In addition, Abstract #376449...